Motley Fool • 5 days ago
These two biotech stocks have been moving in opposite directions. Which one is the better choice at the moment?
Capital Cube • 11 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Alnylam Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ALNY-US. Comparing the performance and risk of Alnylam Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube • 12 days ago
Categories: Yahoo Finance Get free summary analysis Alnylam Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Alnylam Pharmaceuticals, Inc. – Arrowhead Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., PAREXEL International Corporation, Novartis AG Sponsored ADR and Sanofi Sponsored ADR (ARWR-US, REGN-US, PRXL-US, NVS-US and SNY-US) that ... Read more (Read more...)
Benzinga • 16 days ago
On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the ...
Motley Fool • 16 days ago
The biotech used its fourth-quarter earnings to present plans to progress its pipeline, sending shares higher.
American City Business Journals • 16 days ago
Alnylam Pharmaceuticals added $350 million to its market cap on Thursday after the Cambridge biotech posted better-than-expected earnings and provided a rosy outlook for its pipeline in 2017. Late Wednesday, Alnylam (ALNY) reported a net loss of around $113 million in the fourth quarter of 2016, with a loss of $1.32 per share, narrowly beating the consensus Wall Street estimate of a loss of $1.35 per share. The company reported $17.5 million in revenue for the quarter — nearly all of it from a drug development alliance with Sanofi Genzyme — compared to $7.6 million in the fourth quarter of 2015.
Zacks • 16 days ago
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
Associated Press • 17 days ago
The Cambridge, Massachusetts-based company said it had a loss of $1.32 per share. The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...
ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Ask||48.50 x 200|
|Day's Range||45.00 - 47.15|
|52 Week Range||31.38 - 80.11|
|PE Ratio (TTM)||-9.73|
|Earnings Date||May 1, 2017 - May 5, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||62.73|